Trial Profile
Perioperative CapeOx therapy for clinical stage III gastric cancer; a phase II study (OGSG1601)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 20 Apr 2022
Price :
$35
*
At a glance
- Drugs Capecitabine (Primary) ; Oxaliplatin (Primary)
- Indications Adenocarcinoma; Gastric cancer
- Focus Therapeutic Use
- 05 Apr 2022 Results of 3-year follow-up data published in the Oncologist
- 04 Apr 2021 Status changed from active, no longer recruiting to completed.
- 17 Jan 2021 Primary endpoint (pathological response rate) has not been met, as per results presented at the 2021 Gastrointestinal Cancers Symposium